(Q36240749)

13 August 2017

1 reference

title

Pharmacokinetics of antiretroviral therapy in HIV-1-infected children (English)

1 reference

13 August 2017

main subject

anti-retroviral agent

0 references

1 reference

2

Jeroen J A van Kampen

1 reference

13 August 2017

Pieter L A Fraaij

1

1 reference

13 August 2017

David M Burger

series ordinal

3

1 reference

13 August 2017

Ronald de Groot

series ordinal

4

1 reference

13 August 2017

publication date

1 January 2005

1 reference

Clinical Pharmacokinetics

13 August 2017

published in

1 reference

13 August 2017

volume

44

1 reference

13 August 2017

issue

9

1 reference

13 August 2017

page(s)

935-956

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200544090-00004

13 August 2017

exact match

0 references

cites work

Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation

1 reference

12 December 2020

Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

1 reference

12 December 2020

Efavirenz liquid formulation in human immunodeficiency virus-infected children

1 reference

12 December 2020

Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

1 reference

12 December 2020

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

1 reference

12 December 2020

Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.

1 reference

12 December 2020

An open-label pilot study of the efficacy and tolerability of once-daily didanosine versus twice-daily didanosine.

1 reference

12 December 2020

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

1 reference

12 December 2020

Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

1 reference

12 December 2020

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

1 reference

12 December 2020

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team

1 reference

12 December 2020

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection

1 reference

12 December 2020

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

12 December 2020

Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

1 reference

12 December 2020

Rational design of peptide-based HIV proteinase inhibitors

1 reference

12 December 2020

Safety profile and tolerability of amprenavir in patients enrolled in an early access program

1 reference

12 December 2020

Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children

1 reference

12 December 2020

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group

1 reference

12 December 2020

The pharmacokinetics of nelfinavir in HIV-1-infected children

1 reference

12 December 2020

Therapeutic drug monitoring in HIV infection: current status and future directions

1 reference

12 December 2020

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

12 December 2020

Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team

1 reference

12 December 2020

Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response.

1 reference

12 December 2020

Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children

1 reference

12 December 2020

Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children

1 reference

12 December 2020

Pharmacokinetic Optimisation of Antiretroviral Therapy in Patients with HIV Infection

1 reference

12 December 2020

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

1 reference

12 December 2020

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours

1 reference

12 December 2020

Pharmacokinetics of indinavir and low-dose ritonavir in children with HIV-1 infection

1 reference

12 December 2020

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

1 reference

12 December 2020

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

1 reference

12 December 2020

Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.

1 reference

12 December 2020

Pharmacokinetics of orally administered zidovudine in HIV-infected children and adults

1 reference

12 December 2020

Survival in children with perinatally acquired human immunodeficiency virus type 1 infection

1 reference

12 December 2020

PENTA guidelines for the use of antiretroviral therapy, 2004.

1 reference

12 December 2020

Concentration-controlled zidovudine therapy

1 reference

12 December 2020

Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study

1 reference

12 December 2020

Zidovudine pharmacokinetics in premature infants exposed to human immunodeficiency virus

1 reference

12 December 2020

Treatment of antiretroviral-drug-resistant HIV-1 infection

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

1 reference

12 December 2020

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

1 reference

12 December 2020

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

12 December 2020

Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus

1 reference

12 December 2020

A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection

1 reference

12 December 2020

Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 children

1 reference

12 December 2020

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

1 reference

12 December 2020

A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team

1 reference

12 December 2020

Food-induced reduction in bioavailability of didanosine.

1 reference

12 December 2020

Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors

1 reference

12 December 2020

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals

1 reference

12 December 2020

Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir

1 reference

12 December 2020

Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.

1 reference

12 December 2020

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

12 December 2020

Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

1 reference

12 December 2020

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

1 reference

12 December 2020

Timing the ancestor of the HIV-1 pandemic strains

1 reference

12 December 2020

Antiretroviral pharmacokinetics in the paediatric population: a review

1 reference

12 December 2020

Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection.

1 reference

12 December 2020

Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.

1 reference

12 December 2020

Effect of Combination Therapy Including Protease Inhibitors on Mortality among Children and Adolescents Infected with HIV-1

1 reference

12 December 2020

Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children

1 reference

12 December 2020

Therapeutic drug monitoring in children with HIV/AIDS.

1 reference

12 December 2020

Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.

1 reference

12 December 2020

Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates

1 reference

12 December 2020

Pharmacokinetics of zidovudine in infants: a population analysis across studies

1 reference

12 December 2020

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection

1 reference

12 December 2020

Risk to human health from a plethora of simian immunodeficiency viruses in primate bushmeat

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

1 reference

12 December 2020

Reporting of AIDS: tracking HIV morbidity and mortality.

1 reference

12 December 2020

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

12 December 2020

Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection.

1 reference

12 December 2020

Pharmacokinetic evaluation of the combination of zidovudine and didanosine in children with human immunodeficiency virus infection

1 reference

12 December 2020

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

12 December 2020

Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection

1 reference

12 December 2020

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring

1 reference

12 December 2020

Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure

1 reference

12 December 2020

Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three times daily dosing

1 reference

12 December 2020

MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

1 reference

12 December 2020

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection

1 reference

12 December 2020

Changes in indinavir exposure over time: a case study in six HIV-1-infected children.

1 reference

12 December 2020

A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B.

1 reference

12 December 2020

Pros and cons of therapeutic drug monitoring of antiretroviral agents

1 reference

12 December 2020

Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides

1 reference

12 December 2020

The role of clinical pharmacology in optimizing antiretroviral therapy

1 reference

12 December 2020

Position paper on therapeutic drug monitoring of antiretroviral agents

1 reference

12 December 2020

Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children

1 reference

12 December 2020

Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type 1-infected children.

1 reference

12 December 2020

10.2165/00003088-200544090-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

13 August 2017

1034592775

0 references

1 reference